Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

A Phase 1 Open-Label, Dose-Escalation Study of Central Nervous System-Penetrant Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PRT3645, in Patients With Select Advanced or Metastatic Solid Tumors

Friday, October 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Prelude Therapeutics has announced the initiation of a Phase 1 open-label, dose-escalation study for PRT3645, a central nervous system-penetrant CDK4/6 inhibitor. This study aims to evaluate the drug's safety and efficacy in patients with select advanced or metastatic solid tumors. The development reflects Prelude's commitment to addressing significant challenges in cancer treatment.
Price reaction · baseline $2.32 (2023-10-19 close) · hit pre-market · 3 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Initiation of a Phase 1 study indicates progress in drug development.
  • PRT3645 targets advanced or metastatic solid tumors, addressing unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions
Amita Patnaik, Mohamad A. Salkeni, Manish R. Patel, Atrayee Basu-Mallick, Dale Shepard, Christine Lihou, William Sun, Jennifer Xavier, Sri Sahasranaman, Neelesh Sharma, Erika Hamilton

Frequently Asked Questions

What is the purpose of the Phase 1 study for PRT3645?

The Phase 1 study aims to evaluate the safety and efficacy of PRT3645 in patients with advanced or metastatic solid tumors.

What type of drug is PRT3645?

PRT3645 is a central nervous system-penetrant CDK4/6 inhibitor.

Who is conducting the PRT3645 study?

The study is being conducted by Prelude Therapeutics.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3645 CDK4/6 inhibitor solid tumors Prelude Therapeutics cancer treatment
Last updated: Oct 20, 2023

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →